WST

West Pharmaceutical Services, Inc. - 10-Q Summary (Q2 2011)

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for West Pharmaceutical Services, Inc., covering the three and six-month periods ended June 30, 2011. The company operates in two primary segments: Pharmaceutical Packaging Systems and Pharmaceutical Delivery Systems. It is a large accelerated filer incorporated in Pennsylvania.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated net sales increased 9.3% in Q2 and 8.4% YTD compared to 2010. This growth was driven by favorable foreign exchange translation ($18.3M in Q2), modest price increases, and improved product mix. Excluding currency effects, sales grew 2.8% in Q2 and 5.0% YTD.
• Margin Compression: Gross margins declined 2.0 percentage points in Q2 (27.5% vs 29.5%) and 1.1 percentage points YTD. The primary driver was rising raw material costs (natural rubber, synthetic polymers, plastic resin), which reduced margins by approximately 2.3 percentage points.
• Operating Profit Decline: Operating profit decreased $2.7M in Q2 and $2.9M YTD. This was primarily due to increased restructuring charges ($1.3M in Q2, $3.2M YTD) and executive separation costs ($2.1M in Q2 related to the former President/COO).
• Segment Performance: Packaging Systems sales grew 10.6% in Q2, while Delivery Systems sales grew 5.4%. Both segments saw margin pressure from raw material costs and, in the case of Delivery Systems, scheduled price reductions on contract manufacturing agreements.

Guidance, Outlook, and Risks

• Restructuring Plan: The company expects total restructuring charges of $22.0M to $23.0M through 2012. Approximately $5.0M is expected to be incurred in 2011, with the remainder in 2012.
• Capital Expenditures: Full-year 2011 capital spending is projected between $115.0M and $125.0M, a significant increase from $71.1M in 2010. This includes expansion of Daikyo Crystal Zenith syringe capacity and construction of a new corporate office/research facility (expected completion Q1 2013).
• Raw Material Mitigation: Management implemented a temporary raw material surcharge in Q3 to offset cost increases. They expect to fully recover costs through price increases and cost reduction initiatives in the long term.
• Risks: Key risks include the impact of the Japan earthquake/tsunami on supply chain (specifically affiliate Daikyo), volatility in petroleum-based raw material prices, and the ability to pass cost increases to customers. There is also a risk of impairment for long-lived assets related to the 2009 eris acquisition if revenue targets are not met.
• Liquidity: The company maintains a $225.0M revolving credit facility with $204.0M available as of June 30, 2011. A new $50.0M facility was established in June 2011 for the new corporate facility construction.

Investor Verification Checklist

• Raw Material Cost Pass-Through: Verify the effectiveness of the Q3 surcharge and subsequent price increases in offsetting the 2.3 percentage point margin decline caused by raw material costs.
• Restructuring Execution: Monitor the timeline and cost realization of the $22M-$23M restructuring plan, specifically the closure of the U.S. plant and reduction of operations in England.
• Japan Affiliate Impact: Assess any lingering supply chain disruptions or financial impacts from the March 2011 earthquake on Daikyo Seiko, Ltd., a key supplier and affiliate.
• Capital Spending Timing: Track the $115M-$125M capital expenditure plan, particularly the timing of the new China compression-molding plant and the new corporate facility, to ensure cash flow alignment.
• Acquisition Contingencies: Review the status of the eris safety syringe acquisition earn-out, noting the company's assessment that contractual targets will not be achieved, resulting in a $0.8M liability reduction.